Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

A preliminary study of immunoglobulin G glycosylation in people with Down syndrome (CROSBI ID 700692)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | domaća recenzija

Cindrić, Ana ; Krištić, Jasminka ; Mačkić-Đurović, Mirela ; Lauc, Gordan A preliminary study of immunoglobulin G glycosylation in people with Down syndrome // Zbornik radova: 11th ISABS conference on forensic and anthropologic genetics and MAYO clinic lectures in individualized medicine. 2019. str. x-x

Podaci o odgovornosti

Cindrić, Ana ; Krištić, Jasminka ; Mačkić-Đurović, Mirela ; Lauc, Gordan

engleski

A preliminary study of immunoglobulin G glycosylation in people with Down syndrome

Immunoglobulin G (IgG) is among the most abundant glycoproteins in human serum and is also a very important effector molecule of the immune system. The composition of glycans bound to IgG is crucial for its structure and function. Changes in IgG glycosylation are correlated to age and to various diseases. An important symptom of trisomy 21, also known as Down syndrome (DS), are premature signs of aging, which have many notable consequences for the entire organism, especially for the central nervous system and for the immune system. The goal of this preliminary research was to determine whether people with DS show a different IgG glycan composition to their healthy peers and, if so, using IgG glycans as biomarkers of age, to see if these changes are connected to premature aging. The comparison of glycosylation profiles of 13 people with DS and their healthy peers using ultra performance liquid chromatography (UPLC) revealed that there are significant differences in the percentage of certain IgG glycans in DS compared to healthy controls. It was also established that the observed differences in IgG glycan percentages reflect the presence of premature aging in people with DS. Conclusively, in order to see the full effect of DS on IgG glycosylation, more extensive research is needed. This research would be done on larger DS cohorts consisting of individuals with characterized symptoms, so the onset and severity of specific symptoms could be correlated to IgG glycosylation. As a result, IgG glycans may potentially find a use in clinical prognostics for DS.

Down syndrome, immunoglobulin G, glycosylation

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

x-x.

2019.

objavljeno

Podaci o matičnoj publikaciji

Zbornik radova: 11th ISABS conference on forensic and anthropologic genetics and MAYO clinic lectures in individualized medicine

Podaci o skupu

Eleventh ISABS conference on forensic and anthropologic genetics and MAYO clinic lectures in individualized medicine

poster

17.06.2019-22.06.2019

Zagreb, Hrvatska

Povezanost rada

Biologija